{
    "clinical_study": {
        "@rank": "139545", 
        "arm_group": [
            {
                "arm_group_label": "Mesenchymal stem cell arm", 
                "arm_group_type": "Experimental", 
                "description": "Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients received one dose of normal saline."
            }
        ], 
        "brief_summary": {
            "textblock": "Currently, there is no proven effective pharmacologic treatment available for patients with\n      the acute respiratory distress syndrome (ARDS). Mesenchymal stem cells have been shown to be\n      effective in treating several inflammatory diseases. The main purpose of this study is to\n      assess the safety of allogeneic adipose-derived mesenchymal stem cells in patients with\n      ARDS."
        }, 
        "brief_title": "Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "ARDS", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult", 
                "Acute Lung Injury"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. ARDS diagnosed using Berlin definition\n\n          2. Eligible patients were at least 18 years of age had acute onset of ARDS.\n\n          3. Bilateral opacities in chest radiography\n\n          4. No cardiac failure\n\n          5. PaO2/FiO2 ratio < 200\n\n        Exclusion Criteria:\n\n          1. 72 hours after all inclusion criteria met\n\n          2. Pre-existing severe diseases of any major organs\n\n          3. Pregnancy\n\n          4. Pulmonary hypertension\n\n          5. Malignant diseases\n\n          6. HIV infections."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902082", 
            "org_study_id": "MSCs in ARDS"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mesenchymal stem cell arm", 
                "intervention_name": "Mesenchymal stem cells", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Intravenous saline infusion will be designated as placebo."
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ARDS", 
            "mesenchymal stem cells", 
            "Safety", 
            "Cytokines"
        ], 
        "lastchanged_date": "July 14, 2013", 
        "location": {
            "contact": {
                "email": "zgp28037@163.com", 
                "last_name": "Guoping Zheng, MD", 
                "phone": "13385851678"
            }, 
            "contact_backup": {
                "email": "jxu6325@yahoo.com", 
                "last_name": "Jianguo Xu, PhD", 
                "phone": "575-88053995"
            }, 
            "facility": {
                "address": {
                    "city": "Shaoxing", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "312000"
                }, 
                "name": "Shaoxing Second Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Jianguo Xu, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Guoping Zheng, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome", 
        "other_outcome": {
            "description": "IL-6, IL-8, SP-D, TNF-alpha", 
            "measure": "cytokines", 
            "safety_issue": "No", 
            "time_frame": "Day 0 to day 7"
        }, 
        "overall_contact": {
            "email": "zgp28037@163.com", 
            "last_name": "Guoping Zheng, MD", 
            "phone": "13385851678"
        }, 
        "overall_contact_backup": {
            "email": "jxu6325@yahoo.com", 
            "last_name": "Jianguo Xu, PhD", 
            "phone": "575-88053995"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compare the adverse events between mesenchymal stem cell treatment and placebo groups", 
            "safety_issue": "Yes", 
            "time_frame": "From day 0 at the start of treatment to day 28."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Days in hospital ICU free days at day 28 Ventilator free days at day 28", 
            "measure": "Hospital indices by treatment group", 
            "safety_issue": "No", 
            "time_frame": "From admission to discharge"
        }, 
        "source": "Shaoxing Second Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shaoxing Second Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}